Biotie Therapies

Activities: Research & Development

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Biotie makes changes to management team

Appoints new Chief Executive, Chief Financial Officer and Chief Medical Officer
Finance

Acorda offers US$363m for Biotie Therapeutics

Expanding its pipeline of drugs to treat Parkinson's Disease
Research & Development

Michael J Fox Foundation to finance Parkinson\'s trials for Biotie Therapies and Cynapsus Therapeutics

Biotie will receive US$2m, while Cynapsus grant is $500,000
Finance

Biotie purchases option to acquire Neurelis

Provides opportunity to develop late-stage product for treatment of epileptic seizures
Research & Development

Biotie terminates agreement to buy Newron

Newron is exploring all options for safinamide
Finance

Biotie Therapies to acquire Newron for €45m

Will continue to focus on CNS drug development
Research & Development

Biotie to acquire Synosia in all-share deal

Will create a CNS drug development company
Subscribe now